Alzamend Neuro Q3 net loss widens to $5.4M; cash $7.4M; clinical milestones on track

Alzamend Neuro, Inc.

2024-Q3 EPS reported -$1.78

Net loss $5.4M ($0.06/share) vs $2.6M ($0.03/share) a year ago; R&D spend rose to $2.9M.
Cash $7.4M at Jan 31, 2023; expects $14.8M non-dilutive note receivable in Dec 2023.
Phase IIA topline for AL001 (Alzheimer's) expected June 2023; Phase I/IIA for ALZN002 to start March 2023.
Working capital $5.8M; net cash used in operations $6.7M in nine months.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Alzamend Neuro, Inc. reported third quarter ended January 31, 2023 results: net income $5.4 million, or $0.06 per share.

Period: third quarter ended January 31, 2023
Net income: $5.4 million, or $0.06 per share
Result: reported results

Exact text from the filing

Net loss for the three months ended January 31, 2023 was $5.4 million, or $0.06 per share.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Alzamend Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001214659-23-003896

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.